Patents by Inventor Valle Palomo Ruiz

Valle Palomo Ruiz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic GSK-3 allosteric modulators
    Patent number: 9757369
    Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: September 12, 2017
    Assignee: Consejo Superior de Investigaciones Cientificas (CSIC)
    Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
  • Heterocyclic GSK-3 Allosteric Modulators
    Publication number: 20170196850
    Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
    Type: Application
    Filed: January 25, 2017
    Publication date: July 13, 2017
    Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
  • Substituted 5-imino-1,2,4-thiadiazoles that can be used to treat neurodegenerative diseases
    Patent number: 9604947
    Abstract: The present invention is based on the use of a broad family of 5-imino-1,2,4-thiadiazoles as potential new drugs for the treatment of diseases in which PDE7 inhibition is important, specially inflammatory diseases, autoimmune and neurodegenerative disorders. On the other hand, compounds of the 5-imino-1,2,4-thiadiazole family are here described, as well as their synthetic procedures, and they may have great application as drug or drug candidates.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: March 28, 2017
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
    Inventors: Ana Martínez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Daniel Perez Fernandez, Concepción Perez Martín, Ana María Perez Castillo, María Isabel Loza Garcia, María Isabel Cadavid Torres, José Brea Floriani
  • Heterocyclic GSK-3 allosteric modulators
    Patent number: 9585879
    Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: March 7, 2017
    Assignee: Consejo Superior de Investigaciones Cientificas (CSIC)
    Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
  • Heterocyclic GSK-3 Allosteric Modulators
    Publication number: 20160113918
    Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
    Type: Application
    Filed: October 22, 2015
    Publication date: April 28, 2016
    Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
  • Heterocyclic GSK-3 allosteric modulators
    Patent number: 9193688
    Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: November 24, 2015
    Assignee: Consejo Superior de Investigaciones Cientificas
    Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
  • Heterocyclic GSK-3 Allosteric Modulators
    Publication number: 20150057311
    Abstract: The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (GSK-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein GSK-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes.
    Type: Application
    Filed: September 28, 2012
    Publication date: February 26, 2015
    Applicant: Consejo Superior de Investigaciones Cientificas (CSIC)
    Inventors: Ana Martinez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Concepcion Perez Martin, Daniel I. Perez Fernandez, Julio Alberto Reyes Rodriguez
  • SUBSTITUTED 5-IMINO-1,2,4-THIADIAZOLES THAT CAN BE USED TO TREAT NEURODEGENERATIVE DISEASES
    Publication number: 20120225879
    Abstract: The present invention is based on the use of a broad family of 5-imino-1,2,4-thiadiazoles as potential new drugs for the treatment of diseases in which PDE7 inhibition is important, specially inflammatory diseases, autoimmune and neurodegenerative disorders. On the other hand, compounds of the 5-imino-1,2,4-thiadiazole family are here described, as well as their synthetic procedures, and they may have great application as drug or drug candidates.
    Type: Application
    Filed: October 4, 2010
    Publication date: September 6, 2012
    Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFACAS ( CSIC)
    Inventors: Ana Martínez Gil, Carmen Gil Ayuso-Gontan, Valle Palomo Ruiz, Daniel Perez Fernandez, Concepción Perez Martín, Ana María Perez Castillo, María Isabel Loza Garcia, María Isabe Cadavid Torres, José Brea Floriani